Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Study to Evaluate the Maintenance of Efficacy and Long-term Safety of CBL-514 Injection for Reducing Subcutaneous Fat (Stage 1)
Sponsor: Caliway Biopharmaceuticals Co., Ltd.
Summary
A Phase 3b, Multicenter, Two stage, Double-blind, Long term Follow up and Open-label Extension Study of Participants Who have Completed the CBL-0301 or CBL-0302 Study for Reducing Abdominal Subcutaneous Fat (Stage 1)
Official title: A Phase 3b, Multicenter, Two Stage, Double-blind, Long Term Follow up and Open Label Extension Study of Participants Who Have Completed the CBL-0301 or CBL-0302 Study for Reducing Abdominal Subcutaneous Fat (Stage 1)
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
300
Start Date
2026-12
Completion Date
2028-09
Last Updated
2026-10-19
Healthy Volunteers
No
Conditions
Interventions
CBL-514 Injection
Provided as a ready for use injectable CBL-514 solution
0.9 % sodium chloride
Injectable 0.9% Sodium Chloride solution as placebo
Locations (1)
Investigational site 1
Encinitas, California, United States